Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Will Korlym Continue to Drive Corcept's Top Line in 2026?

CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.

Zacks Investment Research • Dec 1, 2025

Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down

CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues.

Zacks Investment Research • Nov 5, 2025

Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript

Corcept Therapeutics Incorporated ( CORT ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean Maduck - President of Endocrinology Joseph K. Belanoff - Co-Founder, President, CEO & Director William Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord Genuity Corp., Research Division David Amsellem - Piper Sandler & Co., Research Division Asim Rana - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.

Seeking Alpha • Nov 5, 2025

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2025. Financial Results “The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had.

Business Wire • Nov 4, 2025

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces.

Business Wire • Oct 28, 2025

Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2025

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical.

Business Wire • Oct 19, 2025

CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

Zacks Investment Research • Oct 15, 2025